JP2023554391A - キナーゼ阻害剤およびそれらの使用 - Google Patents

キナーゼ阻害剤およびそれらの使用 Download PDF

Info

Publication number
JP2023554391A
JP2023554391A JP2023536389A JP2023536389A JP2023554391A JP 2023554391 A JP2023554391 A JP 2023554391A JP 2023536389 A JP2023536389 A JP 2023536389A JP 2023536389 A JP2023536389 A JP 2023536389A JP 2023554391 A JP2023554391 A JP 2023554391A
Authority
JP
Japan
Prior art keywords
optionally substituted
pharmaceutically acceptable
compound
acceptable salt
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023536389A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023554391A5 (cg-RX-API-DMAC10.html
Inventor
チェン チェン
Original Assignee
エイビーエム セラピューティックス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイビーエム セラピューティックス コーポレイション filed Critical エイビーエム セラピューティックス コーポレイション
Publication of JP2023554391A publication Critical patent/JP2023554391A/ja
Publication of JP2023554391A5 publication Critical patent/JP2023554391A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023536389A 2020-12-16 2021-12-16 キナーゼ阻害剤およびそれらの使用 Pending JP2023554391A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063126364P 2020-12-16 2020-12-16
US63/126,364 2020-12-16
PCT/US2021/063724 WO2022133040A1 (en) 2020-12-16 2021-12-16 Kinase inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2023554391A true JP2023554391A (ja) 2023-12-27
JP2023554391A5 JP2023554391A5 (cg-RX-API-DMAC10.html) 2024-12-24

Family

ID=79425572

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023536389A Pending JP2023554391A (ja) 2020-12-16 2021-12-16 キナーゼ阻害剤およびそれらの使用

Country Status (9)

Country Link
US (1) US20240083844A1 (cg-RX-API-DMAC10.html)
EP (1) EP4263501A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023554391A (cg-RX-API-DMAC10.html)
KR (1) KR20230144529A (cg-RX-API-DMAC10.html)
CN (1) CN117083265A (cg-RX-API-DMAC10.html)
AU (1) AU2021401282A1 (cg-RX-API-DMAC10.html)
CA (1) CA3179325A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023006434A (cg-RX-API-DMAC10.html)
WO (1) WO2022133040A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116356017A (zh) * 2022-12-12 2023-06-30 南京腾辰生物科技有限公司 一种甲状腺肿瘤良恶性早期诊断标志物及其应用
WO2025184877A1 (zh) * 2024-03-07 2025-09-12 中国医学科学院基础医学研究所 新免疫检查点grhl3在癌症诊疗和免疫治疗疗效评价中的应用
WO2026064501A1 (en) * 2024-09-18 2026-03-26 The University Of Chicago Reversible and irreversible kinome probes and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006045514A1 (en) * 2004-10-20 2006-05-04 Applied Research Systems Ars Holding N.V. 3-arylamino pyridine derivatives
WO2010007389A1 (en) * 2008-07-15 2010-01-21 Cancer Research Technology Limited 5 -amidothiazole derivatives and their use as checkpoint kinase inhibitors
JP2013507453A (ja) * 2009-10-13 2013-03-04 アロステム セラピューティクス エルエルシー 疾患の処置に有用な新規のmek阻害剤
JP2013542214A (ja) * 2010-10-29 2013-11-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換フェノキシピリジン類
JP2015517574A (ja) * 2012-05-22 2015-06-22 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル がん治療のためのピリミジン化合物
WO2019006548A1 (en) * 2017-07-04 2019-01-10 Trillium Therapeutics Inc. FLUORINATED 2,4-DIAMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE MER (MERTK) AND USES THEREOF

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006045514A1 (en) * 2004-10-20 2006-05-04 Applied Research Systems Ars Holding N.V. 3-arylamino pyridine derivatives
WO2010007389A1 (en) * 2008-07-15 2010-01-21 Cancer Research Technology Limited 5 -amidothiazole derivatives and their use as checkpoint kinase inhibitors
JP2013507453A (ja) * 2009-10-13 2013-03-04 アロステム セラピューティクス エルエルシー 疾患の処置に有用な新規のmek阻害剤
JP2013542214A (ja) * 2010-10-29 2013-11-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換フェノキシピリジン類
JP2015517574A (ja) * 2012-05-22 2015-06-22 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル がん治療のためのピリミジン化合物
WO2019006548A1 (en) * 2017-07-04 2019-01-10 Trillium Therapeutics Inc. FLUORINATED 2,4-DIAMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE MER (MERTK) AND USES THEREOF

Also Published As

Publication number Publication date
EP4263501A1 (en) 2023-10-25
WO2022133040A1 (en) 2022-06-23
KR20230144529A (ko) 2023-10-16
MX2023006434A (es) 2023-06-13
CA3179325A1 (en) 2022-06-23
US20240083844A1 (en) 2024-03-14
CN117083265A (zh) 2023-11-17
AU2021401282A1 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
JP7394768B2 (ja) キナーゼ阻害剤としての環状イミノピリミジン誘導体
RU2687060C2 (ru) Фармацевтические соединения
CN110036007B (zh) 吡啶化合物
RU2686323C2 (ru) Новые соединения и композиции для ингибирования fasn
BR112019012239A2 (pt) compostos de aminotiazol como inibidores de c-kit
TW201833108A (zh) 醯胺類衍生物抑制劑及其製備方法和應用
TW202317532A (zh) Aak1抑制劑及其用途
KR20230144529A (ko) 키나아제 억제제 및 이의 용도
WO2022083657A1 (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
KR20090082486A (ko) 항암성 약물로서 c12-c13 위치에서 개질된 에포틸론 유사체
KR102668390B1 (ko) 신규한 pan-RAF 키나아제 저해제 및 이의 용도
CN115919859A (zh) 一种杂芳基衍生物的药物组合物及其在医药上的应用
KR20170095243A (ko) Pi3kbeta 저해제로서의 헤테로사이클릴 연결된 이미다조피리다진 유도체
JP7823035B2 (ja) アセトアミド-フェニルベンズアミド誘導体およびその使用方法
HK40103623A (en) Kinase inhibitors and uses thereof
RU2801302C2 (ru) Производные циклического иминопиримидина в качестве ингибиторов киназ
RU2792626C1 (ru) Новый ингибитор киназы pan-raf и его применение
TW202408509A (zh) 雜芳基衍生物的藥物組合物及其在醫藥上的應用
WO2022171018A1 (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
TW202320767A (zh) 雜芳基衍生物parp抑制劑及其用途
TW202400171A (zh) 雙環衍生物parp抑制劑及其用途
HK40031627A (en) Cyclic iminopyrimidine derivatives as kinase inhibitors
HK40031627B (en) Cyclic iminopyrimidine derivatives as kinase inhibitors
BR112020005455B1 (pt) Compostos derivados de iminopirimidina cíclica, composição farmacêutica que os compreende, seu uso e método in vitro ou ex vivo para inibir atividade de uma cinase b-raf v600e em uma célula
WO2024153249A1 (zh) 作为pkmyt1抑制剂的化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251028

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260126

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260415

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260717

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260805